Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93778ArticlesСтатьиResearch ArticleVitamin D i mochekamennaya bolezn'Витамин D и мочекаменная болезньKalinchenkoS. YuКалинченкоС. ЮPigarovaE. AПигароваЕ. АGusakovaD. AГусаковаД. АPleshchevaA. VПлещеваА. ВФПКМР ГОУ ВПО Российский университет дружбы народов Минздрава РФ, МоскваФГБУ Эндокринологический научный центр Минздрава РФ, МоскваФГБУ НИИ урологии Минздрава РФ, Москва151220121412VOL 14, NO12 (2012)ТОМ 14, №12 (2012)9710228122021Copyright ©; 2012, Consilium MedicumCopyright ©; 2012, ООО "Консилиум Медикум"2012Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93778

Мочекаменная болезнь (МКБ), или уролитиаз, является частью человеческого существования на протяжении многих тысячелетий. Действительно, камни в почках и мочевом пузыре обнаружены еще у древних людей и египетских мумий. В настоящее время распространенность МКБ в индустриально развитых странах оценивается в популяции в диапазоне от 5 до 12%. Получено достаточное количество доказательств, что МКБ, являясь одной из ведущих нозологий, лечением которой традиционно занимаются урологи, представляет собой важнейшую междисциплинарную проблему, в основе которой лежит тесное патогенетическое взаимодействие разных системных механизмов. Урологи видят лишь конечный продукт таких взаимодействий – конкремент в мочевых путях или почках, который является только «вершиной айсберга». Традиционный хирургический подход к уролитиазу не позволяет сегодня рассчитывать на патогенетическое решение проблемы лечения и профилактики МКБ. Внедрены в практику и активно применяются высокотехнологичные методы лечения МКБ, например дистанционная литотрипсия, рентгеноэндоскопические методы, однако частота рецидивирования уролитиаза при этом все равно остается очень высокой.

National Kidney and Urologic Disease Information Clearinghouse. Adult Kidney Stones. http://kidney.niddk.nih.gov/Kudiseases/pubs/stonesadults/Дасаева Л.А., Шилов Е.М., Шатохина С.Н. Современные представления об этиологии и патогенезе формирования мочевых камней. Нефрология и диализ. 2003; 5 (2). http://www.nephro.ru/magazine/article.php?id=17395Holick M.F., Binkley N.C., Bischoff-Ferrari H.A. et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (7): 1911–30.Worcester E.M., Coe F.L. Clinical practice. Calcium kidney stones. N Engl J Med 2010; 363 (10): 954–63.Balzer K, Bremer M, Schramm S et al. Falls prevention for the elderly. GMS Health Technol Assess 2012; 8 (1).Annweiler C, Fantino B, Gautier J et al. Cognitive effects of vitamin D supplementation in older outpatients visiting a memory clinic: a pre - post study. J Am Geriatr Soc 2012; 60 (4): 793–5.Holick M.F. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002; 9: 87–98.Wasserman R.H., Fullmer C.S. Vitamin D and intestinal calcium transport: facts, speculations and hypotheses. J Nutr 1995; 125: 1971S–1979S.Nemere I, Leathers V, Norman A.W. 1,25-Dihydroxyvitamin D3-mediated intestinal calcium transport. Biochemical identification of lysosomes containing calcium and calcium - binding protein (calbindin-D28K). J Biol Chem 1986; 261: 16106–14.Winaver J, Sylk D.B., Robertson J.S et al. Micropuncture study of the acute renal tubular transport effects of 25-hydroxyvitamin D3 in the dog. Miner Electrolyte Metab 1980; 4: 178–88.Hoenderop J.G., Nilius B, Bindels R.J. Calcium absorption across epithelia. Physiol Rev 2005; 85: 373–422.Hawa N.S., O\'Riordan J.L., Farrow S.M. Functional analysis of vitamin D response elements in the parathyroid hormone gene and a comparison with the osteocalcin gene. Biochem Biophys Res Commun 1996; 228: 352–7.Мирная С.С., Пигарова Е.А., Беляева А.В. и др. Роль кальций - чувствительного рецептора в поддержании системы кальциевого гомеостаза. Остеопороз и остеопатии. 2010; 3: 32–6.Kurose H, Yamaoka K, Okada S et al. 1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] increases insulin - like growth factor I (IGF-I) receptors in clonal osteoblastic cells. Study on interaction of IGF-I and 1,25-(OH)2D3. Endocrinology 1990; 126: 2088–94.Sato T, Ono T, Tuan R.S. 1,25-Dihydroxy vitamin D3 stimulation of TGF-beta expression in chick embryonic calvarial bone. Differentiation 1993; 52: 139–50.Wang D.S., Yamazaki K, Nohtomi K et al. Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast - like cells. J Bone Miner Res 1996; 11: 472–9.Lacey D.L., Grosso L.E., Moser S.A. et al. IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3. J Clin Invest 1993; 91: 1731–42.Alpern R.J., Hebert S.C. Seldin and Giebisch\'s The Kidney (4th edition). Acad Press 2007; p. 1851–90.Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: Nat Acad Press 2010.Cranney C, Horsely T, O\'Donnell S et al. Effectiveness and safety of vitamin D. Evidence Report/Technology Assessment No. 158 prepared by the University of Ottawa Evidence - based Practice Center under Contract No. 290-02.0021. AHRQ Publication No. 07-E013. Rockville, MD: Agency for Healthcare Research and Quality 2007.Norman A.W., Henry H.H. Vitamin D. In: Bowman B.A., Russell R.M., eds. Present Knowledge in Nutrition, 9th ed. Washington DC: ILSI Press, 2006.Плещева А.В., Пигарова Е.А., Дзеранова Л.К. Распространенность дефицита витамина Д и его влияние на физические функции у пациенток в перименопаузе с синдромом хронической усталости (СХУ). Тезисы Всерос. науч. - практ. конф. c междунар. уч. «Алмазовские чтения 2011», посвященной 80-летию со дня рождения академика РАМН В.А.Алмазова. Спб., 2011.El-Hajj Fuleihan G, Nabulsi M, Tamim H et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab 2006; 91: 405–12.Heaney R.P., Davies K.M., Chen T.C. et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204–10.Марова Е.И., Родионова С.С., Рожинская Л.Я., Шварц Г.Я. Альфакальцидол (Альфа-Д3) в профилактике и лечении остеопороза. Метод. рекомендации. М., 1998.Brown A.J., Dusso A.S., Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002; 17 (Suppl. 10): 10–9.Mandel N.S., Mandel G.S. Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J Urol 1989; 142: 1516–21. Sakhaee et al. Kidney Stones 1856. J Clin Endocrinol Metab 2012; 97 (6): 1847–60.Evan A.P., Lingeman J.E., Coe F.L. et al. Crystal - associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 2005; 67: 576–91.Дзеранов Н.К., Лопаткин Н.А. Мочекаменная болезнь. Клин. рекомендации. М.: Оврелей, 2007; с. 296.Looker A.C., Pfeiffer C.M., Lacher D.A. et al. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2003–2004. Am J Clin Nutr 2008; 88: 1519–27.Mac Laughlin J, Holick M.F. Aging decreases the capacity of the human skin to produce vitamin D3. J Clin Invest 1985; 76: 1536–8.Khashayar Sakhaee, Naim M, Maalouf, Bridget Sinnott. Kidney Stones 2012: Pathogenesis, Diagnosis and Management. J Clin Endocrinol Metab 2012; 97 (6): 1847–60.Henneman P.H., Benedict P.H., Forbes A.P., Dudley H.R. Idiopathic hypercaicuria. N Engl J Med 1958; 259: 802–7.Worcester E.M., Coe F.L. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 2008; 28: 120–32.Pak C.Y., Oata M, Lawrence E.C., Snyder W. The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria. J Clin Invest 1974; 54: 387–400.Broadus A.E., Insogna K.L., Lang R et al. A consideration of the hormonal basis and phosphate leak hypothesis of absorptive hypercalciuria. J Clin Endocrinol Metab 1984; 58: 161–9.Insogna K.L., Broadus A.E., Dreyer B.E. et al. Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. J Clin Endocrinol Metab 1985; 61: 490–5.Pak C.Y., East D.A., Sanzenbacher L.J. et al. Gastrointestinal calcium absorption in nephrolithiasis. J Clin Endocrinol Metab 1972; 35: 261–70.Kaplan R.A., Haussler M.R., Deftos L.J. et al. The role of 1,25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 1977; 59: 756–60.Birge S.J., Peck W.A., Berman M, Whedon G.D. Study of calcium absorption in man: a kinetic analysis and physiologic model. J Clin Invest 1969; 48: 1705–13.Maierhofer W.J., Gray R.W., Cheung H.S., Lemann Jr. J. Bone resorption stimulated by elevated serum 1,25-(OH)2-vitamin D concentrations in healthy men. Kidney Int 1983; 24: 555–60.Breslau N.A., Preminger G.M., Adams B.V. et al. Use of ketoconazole to probe the pathogenetic importance of 1,25-dihydroxyvitamin D in absorptive hypercalciuria. J Clin Endocrinol Metab 1992; 75: 1446–52.Barilla D.E., Zerwekh J, Pak C.Y. A critical evaluation of the role of phosphate in the pathogenesis of absorptive hypercalciuria. Miner Electrolyte Metab 1979; 2: 302–9.Zerwekh J.E., Pak C.Y., Kaplan R.A. et al. Pathogenetic role of 1,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J Clin Endocrinol Metab 1980; 51: 381–6.Bushinsky D.A., Grynpas M.D., Nilsson E.L. et al. Stone formation in genetic hypercalciuric rats. Kidney Int 1995; 48: 1705–13.Bushinsky D.A., Asplin J.R., Grynpas M.D. et al. Calcium oxalate stone formation in genetic hypercalciuric stone - forming rats. Kidney Int 2002; 61: 975–87.Li X.Q., Tembe V, Horwitz G.M. et al. Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption. J Clin Invest 1993; 391: 661–7.Tsuruoka S, Bushinsky D.A., Schwartz G.J. Defective renalcalcium reabsorption in genetic hypercalciuric rats. Kidney Int 1997; 51: 1540–7.Karnauskas A.J., van Leeuwen J.P., van den Bemd G.J. et al. Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone - forming rats. J Bone Miner Res 2005; 20: 447–54.Favus M.J., Karnauskas A.J., Parks J.H., Coe F.L. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 2004; 89: 4937–40.Pak C.Y. Etiology and treatment of urolithiasis. Am J Kidney Dis 1991; 18: 624–37.Pak C.Y, Nicar M.J., Peterson R et al. Alack of unique pathophysiologic background for nephrolithiasis of primary hyperparathyroidism. J Clin Endocrinol Metab 1981; 53: 536–42.Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011; 96: 2377–85.Patron P, Gardin J.P., Paillard M. Renal mass and reserve of vitamin D: determinants in primary hyperparathyroidism. Kidney Int 1987; 31: 1174–80.Odvina C.V., Sakhaee K, Heller H.J. et al. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol Res 2007; 35: 123–8.Stamatelou K.K., Francis M.E., Jones C.A. et al. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 2003; 63 (5): 1817–23.Netelenbos J.C., Jongen M.J., van der Vijgh W.J. et al. Vitamin D status in urinary calcium stone formation. Arch Intern Med 1985; 145 (4): 681–4.Khashayar Sakhaee, Naim M, Maalouf et al. Nephrolithiasis - associated bone disease: pathogenesis and treatment options. Kidney Int 2011; 79 (4): 393–403. doi:10.1038/ki.2010.473Penniston K.L., Jones A.N., Nakada S.Y., Hansen K.E. Vitamin D repletion does not alter urinary calcium excretion in healthy postmenopausal women. BJU Int 2009; 104 (10): 1512–6.Elkoushy M.A., Sabbagh R, Unikowsky B, Andonian S. Prevalence and metabolic abnormalities of vitamin D - inadequate patients presenting with urolithiasis to a tertiary stone clinic. Urology 2012; 79 (4): 781–5.Taylor W.H. Renal calculi and self - medication with multivitamin preparations containing vitamin D. Clin Sci 1972; 42: 515–22.Jackson R.D., La Croix A.Z., Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–83.Пигарова E.A., Мирная С.С., Беляева А.В и др. Анализ биохимических предикторов нефролитиаза у пациентов с первичным гиперпаратиреозом. Мат. Всерос. науч.-практ. конф. c междунар. уч. «Алмазовские чтения 2011», посвященной 80-летию со дня рождения академика РАМН В.А.Алмазова. Спб., 2011.